Tubular and Metabolic Dysfunction Following Transplantation

  • Liliana Gradowska
  • Leszek Paczek

Abstract

Metabolic and tubular defects occurring after kidney transplantation are multifactorial and depend on 1) the degree of efficiency of the transplanted organ, 2) side effects of immunosuppressive drugs, 3) late effects of dialysis treatment (e.g., amyloidosis, bone changes), 4) coexistent diseases, often accompanying the kidney failure (e.g., HBV or HCV infection), and 5) consequences of acute and chronic rejections, which by themselves are inflammatory processes.

Keywords

Kidney Transplantation Familial Mediterranean Fever Renal Transplant Recipient Transplant Proc Renal Transplant Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gutshe HU, Delz E, Lüneburg E, et al.: Effect of cyclosporine on the proximal tubular function of the rat kidney (abstract). Kidney Int 637, 1984.Google Scholar
  2. 2.
    Dieperink H, Starklint H, Leyssac PP: Nephrotoxicity of cyclosporine—an animal model of nephrotoxic effect of cyclosporine on overall renal and tubular function in conscious rats. In: BD Kahad, ed, Cyclosporine. Grune and Stratton, New York, p 520, 1984.Google Scholar
  3. 3.
    Battle DC, Gutterman C, Tarka J, Prasad R: Effect of short term cyclosporine A administration on urinary acidification. Clin Nephrol 25 (Suppl): 162–169, 1986.Google Scholar
  4. 4.
    Adu D, Michael J, Turney J, Master P: Hypercalcemia in cyclosporine treated renal allograft recipients. Lancet 2: 370–371, 1983.PubMedCrossRefGoogle Scholar
  5. 5.
    Heering P, Grabensee B: Influence of cyclosporin A on renal tubular function after kidney transplantation. Nephron 59: 66–70, 1991.PubMedCrossRefGoogle Scholar
  6. 6.
    Aguilera S, Deray, Desjobert H, et al.: Effects of cyclosporine on tubular acidification function in patients with idiopatic uveitis. Am J Nephrol 12: 425–430, 1992.PubMedCrossRefGoogle Scholar
  7. 7.
    Gradowska L: Wydzielanie jonu wodorowego przez przes-zczepiona nerke. Pol Arch Med Wewn 61 (5): 373, 1979.PubMedGoogle Scholar
  8. 8.
    Derfus BA, Carrera GF, Komorowski RM, Ryan LM: Severe arthropathy and osteopathy following combined renal pancreas transplantation. Transplantation 53: 678–681, 1992.PubMedCrossRefGoogle Scholar
  9. 9.
    Nordal KP, Dahl E, Halse J, Aksnes L, Thomassen Y, Flatmark A: Aluminium metabolism and bone histology after kidney transplantation, a one year follow-up study. J Clin Endocrinol Metab 74 (5): 1140–1145, 1992.PubMedCrossRefGoogle Scholar
  10. 10.
    Bertolone G, Anchiami M, Bonuci E, et al.: Dynamics of bone aluminium over one year of functioning renal graft. Nephron 64 (4): 540–546, 1993.PubMedCrossRefGoogle Scholar
  11. 11.
    Agarwal S, Owen R: Tendinitis and tendon ruptures in succesful renal transplant recipients. Clin Orthop 252: 270–275, 1990.PubMedGoogle Scholar
  12. 12.
    Partiff AM: Hypercalcemia hyperparathyroidism following renal transplantation: diferential diagnosis management and implications for cell population control in the parathyroid gland. Miner Electrolyte Metab 8: 92–112, 1982.Google Scholar
  13. 13.
    Reid IR: Pathogenesis and treatment of steroid osteoporosis. Clin Endocrinol 30: 83–103, 1989.CrossRefGoogle Scholar
  14. 14.
    Rude RK, Gruber HE, Oldham SB: Cortisone-induced osteoporosis, effect on bone adenylate cyclase. Miner Electrolyte Metab 19 (2): 71–77, 1993.PubMedGoogle Scholar
  15. 15.
    Gallagher JA, Beresford JN, Mac Donald BR, Russell RG: Hormone target cell interactions in human bone. In: Christiansen et al., eds, Osteoporosis. Glostrup Hospital pp 431–439, 1984.Google Scholar
  16. 16.
    Cascio VLO, Bonucci V, Imbimbo E, et al.: Bone loss after glucocorticoid therapy. Calcif Tissue Int 36:435–438, 1984.PubMedCrossRefGoogle Scholar
  17. 17.
    Russel RG, Graveley R, Skjodt H: The effects of cyclosporine A on bone end cartilagt.Br] Rheumatol 32 (Suppl 1): 42–46, 1993.Google Scholar
  18. 18.
    Bosch SA, Raymakers JA, Huber-Bruning O: Acute changes in calcium and bone metabolism during methylprenisolone pulse therapy in rheumatoid arthritis. Br J Rheumatol 27: 215–219, 1988.PubMedCrossRefGoogle Scholar
  19. 19.
    Katz JA, Jee WS, Jaffe II, et al.: Prostaglandin E2 alleviates cyclosporine A induced bone loss in rats. J Bone Miner Res 7 (10): 191–200, 1992.Google Scholar
  20. 20.
    Briner VA, Landmann J, Brunner FP, Thiel G: Cyclosporin A induced transient rise in plasma alkaline phosphatase in kidney transplant patients. Transplant Int 6 (2): 99–107, 1993.CrossRefGoogle Scholar
  21. 21.
    Russel RG, Graveley R, Coxon F, Skjodt H, Del-Poco E, Elford P, Mackenzie A: Cyclosporine A mode of action and effects on bone and joint tissues. Scand J Rheumatol Suppl 95: 8–9, 1992.Google Scholar
  22. 22.
    Sato K, Satoni S, Oguma S, Ohkohchi N, Ozaki H: Relationship between aseptic necrosis of femoral head bone and immunosuppressive therapy, especially CsA administration. Nippon Geka Gakkai Zasshi 94 (8): 832–839, 1993.PubMedGoogle Scholar
  23. 23.
    Lukert BP, Johnson BE, Robinson RG: Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss.,/ Bone Miner Res 7 (9): 1063–1069, 1992.CrossRefGoogle Scholar
  24. 24.
    Kunz D: Treatment of common osteoporosis with fluoride: current trends. Rev Rhum Mal Osteoartic 59: 39–45, 1992.Google Scholar
  25. 25.
    Olbricht T, Benkert G: Glucocorticoid-induced osteoporosis, pathogenesis, prevention and treatment with special regard to rheumatic disease. J Intern Med 234 (3): 237–244, 1993.PubMedCrossRefGoogle Scholar
  26. 26.
    Papapoulos SE, Landsan JO, Bijvoet OL, et al.: The use of biphosphonates in the treatment of osteoporosis. Bone 13 (Suppl I): s41 - s49, 1992.PubMedCrossRefGoogle Scholar
  27. 27.
    Kwan JT, Almond MK, Ewans K, Cunningham J: Changes in total body mineral content and regional bone mineral density in renal patients following renal transplantation. Miner Electrolyte Metab 18: 166–168, 1992.PubMedGoogle Scholar
  28. 28.
    Talataj M, Gradowska L, Durlik M, et al.: Prevention of glucocorticoid-induced osteoporosis with 25-hydroxyvitamin D in kidney transplant patients. Abstracts, XXX Congress of EDTAP, 6, 1993.Google Scholar
  29. 29.
    Rosenbaum RW, Hruska KA, Kokor A, Anderson C, Slatopolsky E: Decreased phosphate reabsorption after renal transplantation: evidence for a mechanism independent of calcium and parathyroid hormone. Kidney Int 19: 568–578, 1981.PubMedCrossRefGoogle Scholar
  30. 30.
    Graf H, Kovarik J, Stummvoll HK, Wolf A, Pinggerra WF: Handling of phosphate by the transplanted kidney. Proc Eur Dial Transplant Assoc 16: 624–628, 1979.PubMedGoogle Scholar
  31. 31.
    Pabico RC, McKenna BA, Freeman RB: Renal function before and after unilateral nephrectomy in renal donors. Kidney Int 8: 166–175, 1975.PubMedCrossRefGoogle Scholar
  32. 32.
    Markell NS, Altura BT, Barbour RL, Altura BK: Ionized and total magnesium levels in cyclosporine-treated renal transplant recipients; relationship with cholesterol and cyclosporine level. Clin Sci (Colch) 85 (3): 315–318, 1993.Google Scholar
  33. 33.
    Nozue T, Kobayashi A, Sako A, et al.: Evidence that cyclosporine causes both intracellular migration and inappropiate urinary excretion of magnesium in rats. Transplantation 55 (2): 346–349, 1993.PubMedCrossRefGoogle Scholar
  34. 34.
    Stethi P, Brown EA, Maini RN, Gower PE: Renal transplantation for dialysis arthropathy. Lancet ii: 448–449, 1988.Google Scholar
  35. 35.
    Campistol JM, Ponz E, Munoz-Gomez J, Oppenheimer F, Ricard MJ, Vilardell J, Andreu J: Renal transplantation for dialysis amyloidosis. Transplant Proc 24: 118–119, 1992.PubMedGoogle Scholar
  36. 36.
    Livneh A, Zemer D, Siegal B, Leor A, Sohar E, Pras M: Colchicine prevents kidney transplant amyloidosis in Familial Mediterranean Fever. Nephron 60:418–122, 1992.PubMedCrossRefGoogle Scholar
  37. 37.
    Harrison KL, Alpers ChE, Daris CL: De novo amyloidosis in a renal allograft: a case report and review of the literature. Am J Kidney Dis 22: 468–476, 1993.PubMedGoogle Scholar
  38. 38.
    Burack DA, Gryffith BP, Thompson ME, Kahl LE: Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. Am J Med 42: 141–145, 1992.CrossRefGoogle Scholar
  39. 39.
    Delaney V, Sumrani N, Daskelakis P, Hong JH, Sommer BG: Hyperuricemia and gout in renal allograft recipients. Transplant Proc 24: 1773–1774, 1992.PubMedGoogle Scholar
  40. 40.
    Lin HY, Rocher LL, Me Quillan MA, Schaltz S, Pallella TD, Fox IH: Cyclosporine-induced hyperuricemia and gout. N Engl J Med 321: 287–292, 1989.PubMedCrossRefGoogle Scholar
  41. 41.
    Noordzij TC, Leunissen KML, Ven Hooff JP: Renal handling of urate and the incidence of gout arthritis during cyclosporine and duvetic ure. Transplantation 52: 64–66, 1991.PubMedCrossRefGoogle Scholar
  42. 42.
    Marcen R, Gallego N, Gamez C, Orofino L, Ortuno J: Hyperuricemia after kidney transplantation in patients treated with cyclosporine. Am J Med 93: 354–355, 1992.PubMedCrossRefGoogle Scholar
  43. 43.
    Julian BA, Guarles LD, Niemann KMW: Musculoskeletal complications after renal transplantation: pathogenesis and treatment. Am J Kidney Dis 19: 99–120, 1992.PubMedGoogle Scholar
  44. 44.
    Marais GE, Larson KK: Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. Ann Intern Med 112: 228–230, 1990.PubMedCrossRefGoogle Scholar
  45. 45.
    Abouna GM, Kumar MSA, Silva OSG, Samhan M, Cheriyan G, At Abdulla I., White AG: Reversal of myocardial dysfunction following renal transplantation. Transplant Proc 25: 1034–1035, 1993.PubMedGoogle Scholar
  46. 46.
    Castelao AM, Grino JM, Anders E, Gliverent S, Seron D, Castineiras MJ, Roca M, Galceran JM, Gonzalez MT, Alisina J: HMGCoA reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation. Transplant Proc 25: 1043–1046, 1993.PubMedGoogle Scholar
  47. 47.
    Yoshimura N, Oka T, Okamato M, Ohmori Y: The effect of Pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 53: 94–99, 1992.PubMedCrossRefGoogle Scholar
  48. 48.
    Nicholas ML, Alexandre GPJ: The evolution of hyperlipidemia late after renal transplantation. Proc Eur Dial Transplant Assoc 16: 339, 1979.PubMedGoogle Scholar
  49. 49.
    Moore R, Thomas D, Morgan E, Wheeler D, Griffin P, Salaman J, Rees A: Abnormal lipid and lipoprotein profiles following renal transplantation. Transplant Proc 25: 1060–1061, 1993.PubMedGoogle Scholar
  50. 50.
    Webb AT, Plant M, Reaveley DA, O’Donnell M, Luck VA, O’Connor B, Seed M, Brown EA: Lipid and lipoprotein (a) concentration in transplant patients.Google Scholar
  51. 51.
    Diamond JR: In: WF Keane, JH Stein, eds, Contemporary Issues in Nephrology. Vol 24: Lipids and Renal Disease. Churchill Livingstone, New York, 109–1, 1990.Google Scholar
  52. 52.
    Schmitz PG, Kasiske BL, O’Donnel MP, Keane WF: Lipids and progressive renal injury. Semin Nephrol 9: 354–369, 1989.PubMedGoogle Scholar
  53. 53.
    Appel G: Lipid abnormalites in renal disease. Kidney Int 39: 169–183, 1991.PubMedCrossRefGoogle Scholar
  54. 54.
    Scott J: Lipoprotein (a): trombogenesis linked to athero-genesis at last. Nature 341: 22–23, 1989.PubMedCrossRefGoogle Scholar
  55. 55.
    Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolobon G, Quinci GB: Lipoprotein Lp (a) and the risk for myocardial infarction. Atherosclerosis 38: 51–61, 1991.CrossRefGoogle Scholar
  56. 56.
    Hopper J, Ryan P, Lee JC, Rosenman W: Lipoid nephrosis in 31 adult patients. Medicine (Baltimore) 49: 321–341, 1970.CrossRefGoogle Scholar
  57. 57.
    Curry RC, Roberts WC: Status of the coronary arteries in the nephrotic syndrome. Am J Med 63: 183–192, 1977.PubMedCrossRefGoogle Scholar
  58. 58.
    Traindl O, Reaoling S, Frauz M, Watschinger B, Klauser R, Pidlich H, Widhelm K, Pohonka E, Kovorik J: Treatment of hyperlipidemic kidney graft recipients with Lovastatin: effect on LDL-cholesterol and lipoprotein (a). Nephron 62: 394–398, 1992.PubMedCrossRefGoogle Scholar
  59. 59.
    Kasiske BL, Tortorice KL, Heim-Dilthoy KL, Goryance JM, Rao V: Lovastatin treatment of hypercholesterolemia in renal transplant recipients. Transplantation 49: 95, 1990.PubMedCrossRefGoogle Scholar
  60. 60.
    Chueng AK, De Vault GA, Gregory MC: A perspective study on treatment of hypercholesterolemia with Lovastatin in renal transplant patients receiving cyclosporine. J Am Soc Nephrol 3: 1884–1891, 1993.Google Scholar
  61. 61.
    Knigkt RJ, Vathsala A, Schoeuberg L, Cornel S, Weinberg RB, Goldstein RA, Lewis RM, Van Buren CT, Kohen BD: Treatment of hyperlipidemia in renal transplant patients with gemfibrozil and dietary modification. Transplantation 53: 224–225, 1991.Google Scholar
  62. 62.
    Gill IS, Hodge EE, Novick AC, Steinmuller DR, Garred D: Impact of obesity on renal transplantation. Transplant Proc 25: 1047–1048, 1993.PubMedGoogle Scholar
  63. 63.
    Holley JL, Shapiro R, Lopatin WB, Tzakis AG, Hakela TR, Starz TE: Obesity as a risk factor following cadaver renal transplantation. Transplantation 49: 387–389, 1990.PubMedCrossRefGoogle Scholar
  64. 64.
    Flechner SM, Kolbeiusson ME, Tarn J, Lum B: The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients. Transplantation 47: 806–810, 1989.PubMedCrossRefGoogle Scholar
  65. 65.
    Rao M, Jacob CK, Shastry JCM: Post-renal transplant diabetes mellitus—retrospective study. Nephrol Dial Transplant 7: 1039–1042, 1992.PubMedGoogle Scholar
  66. 66.
    Basadonna G, Matas AJ, Nojarian JS: Kidney transplantation in diabetic patient: The University of Minnesota experience. Kidney Int 42:S-193-S-196,1992.Google Scholar
  67. 67.
    Ekstrand AV, Eriksson JG, Gronhagen-Riska C, Ahonen PJ, Groop LC: Insulin resistance and insulin deficiency in the pathogenesis of posttransplantation diabetes in man. Transplantation 53: 563–569, 1992.PubMedCrossRefGoogle Scholar
  68. 68.
    Feinstein EI, Wanner Ch, Bohler J, Horl WH: Endocrine and metabolic disorders following kidney transplantation. Am J Nephrol 12: 363–368, 1992.PubMedCrossRefGoogle Scholar
  69. 69.
    Hricik DE, Bartucci MR, Moir EJ, Mayes JT, Schulak JA: Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation 51: 374–377, 1991.PubMedCrossRefGoogle Scholar
  70. 70.
    Ruiz JO, Simmons RL, Callender CO, Kjellstrand CM, Buselmeier TJ, Nojerien JS: Steroid-induced diabetes in renal transplant patients: pathogenetic factors and prognosis Surgery 73: 759, 1973.PubMedGoogle Scholar
  71. 71.
    Seemayer TA, Murphy GF, Marliss EB: Glucose tolerance in the rat. Diabetes 34: 1309, 1985.PubMedCrossRefGoogle Scholar
  72. 72.
    Najarian JS, Kaufmant DB, Fryd DS, Mc Hugh L, Mauer SM, Remsay RC, Kennedy WR, Navarro X., Goetz FC, Sutherland DER: Long-term survival following kidney transplantation in 100 Type I diabetic patients. Transplantation 47: 106–113, 1989.PubMedCrossRefGoogle Scholar
  73. 73.
    Kelly JJ, Walker RG, Kinceid-Smith P: De novo diabetic nodular glomerulosclerosis in renal allograft. Transplantation 53: 688–689, 1992.PubMedCrossRefGoogle Scholar
  74. 74.
    Innes A, Pol CR, Deunis MJ, Ryan JJ, Morgan AG, Burolen RR: Posttransplant erythrocytosis and immunosuppression with cyclosporin: a case control study. Nephrol Dial Transplant 6: 588–591, 1991.PubMedCrossRefGoogle Scholar
  75. 75.
    Wolff M, Jelkmann W: Erythropoiesis and erythropoietin levels in renal transplant recipients. Klin Wochensch 69: 53–58, 1991.CrossRefGoogle Scholar
  76. 76.
    Hammond D, Winnick S: Paraneoplastic erythrocytosis and ectopic erythropoietins. Ann N Y Acad Sei 230: 219–227, 1974.CrossRefGoogle Scholar
  77. 77.
    Reil K, Koziak K, Jarzyto I, Lao M, Gaciong Z: Correction of posttransplant erythrocytosis with enalapril. Transplant Int, in press.Google Scholar
  78. 78.
    Sauron C, Bertoux P, Bertoux F, Alamartine E, Diob N, Broyet C, Hecini J: New insights and treatment in posttransplant polycythemia (erythrocytosis) of renal recipients. Transplant Proc 25: 1032–1033, 1993.PubMedGoogle Scholar
  79. 79.
    Gaston RS, Julian BA, Barker CV, Diethelm AG, Curtis JJ: Enalapril: safe and effective therapy for posttransplant erythrocytosis. Transplant Proc 25: 1029–1031, 1993.PubMedGoogle Scholar
  80. 80.
    Conlon P, Fawell J, Donohoe J, Carmody M, Walsche JJ: The beneficial effect of enalapril on erythrocytosis after renal transplantation. Transplantation 56: 217–219, 1993.PubMedCrossRefGoogle Scholar
  81. 81.
    Brunner HR: ACE inhibitors in renal disease. Kidney Int 42: 463–479, 1992.PubMedCrossRefGoogle Scholar
  82. 82.
    Hermans MP, Brichard SM, Colin I, Borgies P, Ketelslegers JM, Lambert AE: Long-term reduction of microalbuminuria after 3 years of angiotensin-converting enzyme inhibitors by Perindopril in hypertensive insulin-treated diabetic patients. Am J Med 92 (Suppl 4B): 102S - 107S, 1992.PubMedCrossRefGoogle Scholar
  83. 83.
    Bromberg JS, Alfrey EJ, Barker CF, Chavin KD, Dafoe DC, Holland T, Noji A, Perloff LJ, Zellers LA, Grossman RA: Adrenal suppression and steroid supplementation in renal transplant recipients. Transplantation 51: 385–390, 1991.PubMedCrossRefGoogle Scholar
  84. 84.
    Handschumacher RE: Immunosuppressive agents. In: AG Goodman, TW Rail, AS Nies, P Toylor, eds, The pharmacological Basis of Therapeutics. Pergamon Press, New York, p 14–1276, 1991.Google Scholar
  85. 85.
    Rota S, Rembaldi A, Gaspari F, Noris M, Daina E, Benigni A, Aerna A, Donadelli R, Remuzzi G, Garattini S: Methyl-prednisolone dosage effects on peripheral lymphocyte sub-populations and eicosanoid synthesis. Kidney Int 42:981–990Google Scholar
  86. 86.
    Haynes RC: Adrenocorticotropic hormone: adrenocortical steroids and their synthetic analogs: inhibitors of the synthesis and actions of adrenocortical hormones. In: AG Goodman, TW Rail, SA Nies, P Taylor, eds, The Pharmacological Basis of Therapeutics. Pergamon Press, New York, p 14–1276, 1991.Google Scholar
  87. 87.
    Norman DJ: Antilymphocyte antibodies in the treatment of allograft rejection: targets, mechanisms of action, monitoring and efficacy. Semin Nephrol 12: 315–324, 1992.PubMedGoogle Scholar
  88. 88.
    Leimenstoll G, Zabel P, Schroeder P, Schlaak M, Nieder-mayer W: Suppression of OKT-3-induced Tumor Necrosis Factor Alfa formation by Pentoxifylline in renal transplant recipients. Transplant Proc 25: 561–563, 1993.PubMedGoogle Scholar
  89. 89.
    Kreis H: Antilymphocyte globulin in kidney transplantation. Kidney Int 42:S-188-S-192,1992.Google Scholar
  90. 90.
    Shihab F, Barry JM, Bennet WM, Mayer MM, Norman DJ: Cytokine-related encephalopathy induced by OKT-3: incidence and predisposing factors. Transplant Proc 25:564–565Google Scholar
  91. 91.
    Berge RJM, Reasveld MHM, van Diepen FNJ, Hack CE: Activation of coagulation and fibrinolysis during treatment with OKT-3. Transplant Proc 25: 566–567, 1993.PubMedGoogle Scholar
  92. 92.
    Alegre ML, Gasteldello K, Abramowicz D, Kiunaert P, Vereestreeten P, De Pauw L, Vandenebelle P, Moser M, Leo O, Goldmen M: Evidence that pentoxifylline reduces anti- CD3 monoclonal antibody induced cytokine release syndrome. Transplantation 52: 674–679, 1991.PubMedCrossRefGoogle Scholar
  93. 93.
    Janssen F, Van Damme-Lombaerts R, Van Dyck M, Hall M, Proesmans W, Goos G, Kinnaert P: Effects of recombinant human growth hormone on graft function in renal transplanted children and adoltescents: three-year experience of a Belgian study group. Transplant Proc 25: 1049–1050, 1993.PubMedGoogle Scholar
  94. 94.
    Van Dap C, Jobs KL, Donohoue PA, Bock GH, Fivush BA, Hormau WE: Accelerated growth rates in children treated with hormone after renal transplantation. J Pediatr 120: 244–250, 1992.CrossRefGoogle Scholar
  95. 95.
    Neberg G, Nilsson B, Hallste G, Haljamac V, Norden G, Blohme I: Renal transplantation in elderly patients: survival and complications. Transplant Proc 25: 1062–1063, 1993.Google Scholar
  96. 96.
    Schulak JA, Mayes JT, Jonston KH, Hricik DE: Kidney transplantation in patients aged sixty years and older. Surgery 108: 7–733, 1990.Google Scholar
  97. 97.
    Salmela KT, Kyllonen LE J, Holmberg Ch, Gronhagen-Riska C: Impaired renal function after pregnancy in renal transplant recipients. Transplantation 56: 1372–1375, 1993.PubMedCrossRefGoogle Scholar
  98. 98.
    Bumgardner GL, Matas AJ: Transplantation and pregnancy. Transplantation Rev 6: 139–162, 1992.CrossRefGoogle Scholar
  99. Tubular and Metabolic Dysfunction Following Transplantation 1Google Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Liliana Gradowska
    • 1
  • Leszek Paczek
    • 2
  1. 1.Department of Immunotherapy The Transplantation InstituteSchool of MedicineWarsawPoland
  2. 2.The Transplantation InstituteSchool of MedicineWarsawPoland

Personalised recommendations